Cargando…

Plasma Thymidine Kinase Activity as a Novel Biomarker in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibitors

SIMPLE SUMMARY: Immune checkpoint inhibitors (ICI) are effective in fractions of patients with disseminated melanoma. Significant toxicity can also occur from the treatments, that, in addition, are expensive. It is therefore important to increase the knowledge of predictive factors and their efficac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Costa Svedman, Fernanda, Jalsenius, Marie, Höiom, Veronica, Grozman, Vitali, Bergqvist, Mattias, Söderdahl, Fabian, Eriksson, Hanna, Rotstein, Samuel, Ny, Lars, Ascierto, Paolo A., Brage, Suzanne Egyhazi, Helgadottir, Hildur
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833501/ https://www.ncbi.nlm.nih.gov/pubmed/35158970 http://dx.doi.org/10.3390/cancers14030702

Ejemplares similares

Proliferation and Immune Response Gene Signatures Associated with Clinical Outcome to Immunotherapy and Targeted Therapy in Metastatic Cutaneous Malignant Melanoma
por: Costa Svedman, Fernanda, et al.
Publicado: (2022)

Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status
por: Das, Ishani, et al.
Publicado: (2019)

The genetics of uveal melanoma: current insights
por: Helgadottir, Hildur, et al.
Publicado: (2016)

Extracellular microvesicle microRNAs as predictive biomarkers for targeted therapy in metastastic cutaneous malignant melanoma
por: Svedman, Fernanda Costa, et al.
Publicado: (2018)

Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells
por: Azimi, Alireza, et al.
Publicado: (2017)

Chemokine Analysis in Patients with Metastatic Uveal Melanoma Suggests a Role for CCL21 Signaling in Combined Epigenetic Therapy and Checkpoint Immunotherapy
por: Sah, Vasu R., et al.
Publicado: (2023)

High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families
por: Helgadottir, Hildur, et al.
Publicado: (2014)

Multiple Primary Melanoma Incidence Trends Over Five Decades: A Nationwide Population-Based Study
por: Helgadottir, Hildur, et al.
Publicado: (2020)

AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanoma
por: Das, Ishani, et al.
Publicado: (2020)

Silencing of CEBPB-AS1 modulates CEBPB expression and resensitizes BRAF-inhibitor resistant melanoma cells to vemurafenib
por: Vidarsdottir, Linda, et al.
Publicado: (2020)

Serial evaluation of serum thymidine kinase activity is prognostic in women with newly diagnosed metastatic breast cancer
por: Larsson, Anna-Maria, et al.
Publicado: (2020)

Evaluation of serum thymidine kinase 1 activity as a biomarker for treatment effectiveness and prediction of relapse in dogs with non‐Hodgkin lymphoma
por: Boyé, Pierre, et al.
Publicado: (2019)

Survival after introduction of adjuvant treatment in stage III melanoma: a nationwide registry-based study
por: Helgadottir, Hildur, et al.
Publicado: (2023)

Prognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer
por: Matikas, A., et al.
Publicado: (2021)

Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations
por: Helgadottir, Hildur, et al.
Publicado: (2020)

THYMIDINE DEGRADATION PRODUCTS IN PLANT TISSUES LABELED WITH TRITIATED THYMIDINE
por: Takats, S. T., et al.
Publicado: (1963)

THYMIDINE TRIPHOSPHATE SYNTHESIS IN TETRAHYMENA : I. Studies on Thymidine Kinase
por: Shoup, G. D., et al.
Publicado: (1966)

INDUCIBILITY OF THYMIDINE KINASE BY THYMIDINE AS A FUNCTION OF INTERPHASE STAGE
por: Hotta, Yasuo, et al.
Publicado: (1965)

Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma
por: Falkenius, Johan, et al.
Publicado: (2017)

Negative Cooperative Binding of Thymidine, Ordered Substrate Binding, and Product Release of Human Mitochondrial Thymidine Kinase 2 Explain Its Complex Kinetic Properties and Physiological Functions
por: Wang, Liya, et al.
Publicado: (2018)

Pathways of thymidine hypermodification
por: Lee, Yan-Jiun, et al.
Publicado: (2021)

Anticancer activity of a thymidine quinoxaline conjugate is modulated by cytosolic thymidine pathways
por: Wei, Qiong, et al.
Publicado: (2015)

Plasma thymidine kinase 1 activity and outcome of ER+ HER2− metastatic breast cancer patients treated with palbociclib and endocrine therapy
por: Cabel, Luc, et al.
Publicado: (2020)

Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment
por: Helgadottir, Hildur, et al.
Publicado: (2018)

Melanoma‐specific survival before and after inclusion in a familial melanoma dermatologic surveillance program in CDKN2A mutation carriers and non‐carriers
por: Pissa, Maria, et al.
Publicado: (2022)

ΔNp73 regulates the expression of the multidrug-resistance genes ABCB1 and ABCB5 in breast cancer and melanoma cells - a short report
por: Sakil, Habib A. M., et al.
Publicado: (2017)

Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study
por: Jespersen, Henrik, et al.
Publicado: (2019)

3'-Amino thymidine affinity matrix for the purification of herpes simplex virus thymidine kinase.
por: Tung, P. P., et al.
Publicado: (1996)

Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy
por: Bonechi, Martina, et al.
Publicado: (2018)

Investigation on Cell Proliferation with a New Antibody against Thymidine Kinase 1
por: Wang, Naining, et al.
Publicado: (2001)

Thymidine kinase in breast cancer.
por: Robertson, J. F., et al.
Publicado: (1990)

Depletion of plasma thymidine results in growth retardation and mitochondrial myopathy in mice overexpressing human thymidine phosphorylase
por: Harada, Naomoto, et al.
Publicado: (2023)

Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226)
por: Bergqvist, Mattias, et al.
Publicado: (2023)

Serum thymidine kinase in acute leukaemia.
por: Hagberg, H., et al.
Publicado: (1984)

Incorporation of Thymidine in the Cytoplasm of Amoeba proteus
por: Plaut, W., et al.
Publicado: (1958)

Thymidine Analogues for Tracking DNA Synthesis
por: Cavanagh, Brenton L., et al.
Publicado: (2011)

Quaternary structures of recombinant, cellular, and serum forms of Thymidine Kinase 1 from dogs and humans
por: Hanan, Sharif, et al.
Publicado: (2012)

Metabolic markers GAPDH, PKM2, ATP5B and BEC-index in advanced serous ovarian cancer
por: Hjerpe, Elisabet, et al.
Publicado: (2013)

SuperLie and problems (to be) solved with it
por: Grozman, P, et al.
Publicado: (2003)

Feline thymidine kinase 1: molecular characterization and evaluation of its serum form as a diagnostic biomarker
por: Wang, Liya, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n63jl4brk425lfnjfn67jt0hg7